Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 3/2014

01-06-2014 | Research Article

Inappropriate prescribing in patients accessing specialist palliative day care services

Authors: A. Todd, H. Nazar, S. Pearson, I. Andrew, L. Baker, A. Husband

Published in: International Journal of Clinical Pharmacy | Issue 3/2014

Login to get access

Abstract

Background For patients accessing specialist palliative care day services, medication is prescribed routinely to manage acute symptoms, treat long-term conditions or prevent adverse events associated with these conditions. As such, the pharmacotherapeutic burden for these patients is high and polypharmacy is common. Consequently, the risk of these patients developing drug-related toxicities through drug–drug interactions is exacerbated. Medication use in this group should, therefore, be evaluated regularly to align with achievable therapeutic outcomes considering remaining life expectancy. Objective To (1) assess the prevalence of inappropriate medication use; (2) identify potential drug–drug interactions; and, (3) determine how many potential drug–drug interactions could be prevented by discontinuing inappropriate medication. Setting A specialist tertiary care palliative care centre in Northern England serving a population of 330,000. Main outcome measure Prescribing of inappropriate medication. Method Medication histories for patients accessing a specialist palliative day care centre were established and a modified Delphi method was used to reach consensus of medication appropriateness. The Delphi method utilized a framework considering the following factors: remaining life expectancy of the patient, time until benefit of the treatment, goals of care and treatment targets. Potential drug interactions were established using drug interaction recognition software and categorised by their ability to cause harm. Results A total number of 132 patients were assessed during the study period who were prescribed 1,532 (mean = 12/patient) medications; 238 (16 %) were considered inappropriate in the context of limited life expectancy. The most common class of medications considered inappropriate were the statins, observed in 35 (27 %) patients. A total of 267 potential drug–drug interactions were identified; 112 were clinically significant and 155 were not considered clinically significant. Discontinuation of inappropriate medication would reduce the total number of medications taken to 1,294 (mean = 10/patient) and prevent 31 clinically significant potential drug–drug interactions. Conclusion Patients accessing specialist palliative day care services take many inappropriate medications. These medications not only increase the pharmacotherapeutic burden for the patient but they also contribute to potential drug–drug interactions. These patients should have their medication reviewed in the context of life limiting illness aligned with achievable therapeutic outcomes.
Literature
1.
go back to reference Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med. 2003;17:310–4.PubMedCrossRef Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med. 2003;17:310–4.PubMedCrossRef
2.
go back to reference Sera L, McPherson ML, Holmes HM. Commonly prescribed medications in a population of hospice patients. Am J Hosp Palliat Care. 2013; Feb 12 (Epub ahead of print). Sera L, McPherson ML, Holmes HM. Commonly prescribed medications in a population of hospice patients. Am J Hosp Palliat Care. 2013; Feb 12 (Epub ahead of print).
3.
go back to reference Koh NY, Koo WH. Polypharmacy in palliative care: can it be reduced? Singap Med J. 2002;43(6):279–83. Koh NY, Koo WH. Polypharmacy in palliative care: can it be reduced? Singap Med J. 2002;43(6):279–83.
4.
go back to reference Rottlaender D, Scherner M, Schneider T, Erdmann E. Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr. 2007;132(4):139–44.PubMedCrossRef Rottlaender D, Scherner M, Schneider T, Erdmann E. Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr. 2007;132(4):139–44.PubMedCrossRef
5.
go back to reference Riechelmann RP, Zimmermann C, Chin SN, Wang L, O’Carroll A, Zarinehbaf S, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manag. 2008;35:535–43.CrossRef Riechelmann RP, Zimmermann C, Chin SN, Wang L, O’Carroll A, Zarinehbaf S, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manag. 2008;35:535–43.CrossRef
6.
go back to reference Girre V, Arkoub H, Puts MT, Vantelon C, Blanchard F, Droz JP, et al. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol. 2011;78:220–6.PubMedCrossRef Girre V, Arkoub H, Puts MT, Vantelon C, Blanchard F, Droz JP, et al. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol. 2011;78:220–6.PubMedCrossRef
7.
go back to reference Currow DC, Abernethy AP. Frameworks for approaching prescribing at the end of life. Arch Intern Med. 2006;166(21):2404.PubMed Currow DC, Abernethy AP. Frameworks for approaching prescribing at the end of life. Arch Intern Med. 2006;166(21):2404.PubMed
8.
go back to reference Hall PS, Lord SR, El-Laboudi A, Seymour MT. Non-cancer medications for patients with incurable cancer: time to stop and think? Br J Gen Pract. 2010;60(573):243–4.PubMedCentralPubMedCrossRef Hall PS, Lord SR, El-Laboudi A, Seymour MT. Non-cancer medications for patients with incurable cancer: time to stop and think? Br J Gen Pract. 2010;60(573):243–4.PubMedCentralPubMedCrossRef
9.
10.
go back to reference Nicholson A, Andrew I, Etherington R, Gamlin R, Lovel T, Lloyd J. Futile and inappropriate prescribing: an assessment of the issue in a series of patients admitted to a specialist palliative care unit. Int J Pharm Pract. 2001;9(S1):72.CrossRef Nicholson A, Andrew I, Etherington R, Gamlin R, Lovel T, Lloyd J. Futile and inappropriate prescribing: an assessment of the issue in a series of patients admitted to a specialist palliative care unit. Int J Pharm Pract. 2001;9(S1):72.CrossRef
12.
go back to reference Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS ONE. 2011;6(6):e20476.PubMedCentralPubMedCrossRef Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS ONE. 2011;6(6):e20476.PubMedCentralPubMedCrossRef
13.
go back to reference Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605–9.PubMedCrossRef Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605–9.PubMedCrossRef
14.
go back to reference Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12(10):1–8. Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12(10):1–8.
16.
go back to reference Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.PubMedCrossRef Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.PubMedCrossRef
17.
go back to reference Baxter K, Preston CL. Stockley’s drug interactions. 10th ed. UK: Pharmaceutical Press; 2013. ISBN 978 0 85711 061 9. Baxter K, Preston CL. Stockley’s drug interactions. 10th ed. UK: Pharmaceutical Press; 2013. ISBN 978 0 85711 061 9.
19.
go back to reference Todd A, Williamson S, Husband A, Baqir W, Mahony M. Patients with advanced lung cancer: is there scope to discontinue inappropriate medication? Int J Clin Pharm. 2013;35:181–4.PubMedCrossRef Todd A, Williamson S, Husband A, Baqir W, Mahony M. Patients with advanced lung cancer: is there scope to discontinue inappropriate medication? Int J Clin Pharm. 2013;35:181–4.PubMedCrossRef
20.
go back to reference Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer. 2009;17(6):745–8.PubMedCrossRef Riechelmann RP, Krzyzanowska MK, Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer. 2009;17(6):745–8.PubMedCrossRef
21.
go back to reference Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B, et al. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer. 2011;19:1313–8.PubMedCrossRef Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B, et al. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer. 2011;19:1313–8.PubMedCrossRef
22.
go back to reference van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22(10):2334–41.PubMedCrossRef van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22(10):2334–41.PubMedCrossRef
23.
go back to reference Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005;28(3):223–7.PubMedCrossRef Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005;28(3):223–7.PubMedCrossRef
25.
go back to reference Steiness E. Diuretics, digitalis and arrhythmias. Acta Med Scand Suppl. 1981;647:75–8.PubMed Steiness E. Diuretics, digitalis and arrhythmias. Acta Med Scand Suppl. 1981;647:75–8.PubMed
26.
go back to reference British National Formulary 64, September 2012. UK: Pharmaceutical Press. ISBN 978-0857110657. British National Formulary 64, September 2012. UK: Pharmaceutical Press. ISBN 978-0857110657.
27.
go back to reference Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Renal Insufficiency and Cancer Medications (IRMA) Study Group: prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376–84.PubMedCrossRef Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Renal Insufficiency and Cancer Medications (IRMA) Study Group: prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376–84.PubMedCrossRef
28.
29.
go back to reference Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–24.PubMedCrossRef Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–24.PubMedCrossRef
30.
go back to reference Hanlon JT, Schmader KE, Samsa GP. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45:1045–51.PubMedCrossRef Hanlon JT, Schmader KE, Samsa GP. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45:1045–51.PubMedCrossRef
31.
go back to reference Gallagher P, Ryan C, Byrne S. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert Doctors To Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72–83.PubMedCrossRef Gallagher P, Ryan C, Byrne S. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert Doctors To Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72–83.PubMedCrossRef
32.
go back to reference Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9.
33.
go back to reference Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk: pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623.PubMedCrossRef Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk: pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623.PubMedCrossRef
34.
go back to reference Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef
35.
go back to reference Callahan AS. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. Curr Atheroscler Rep. 2003;5(1):33–7.PubMedCrossRef Callahan AS. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. Curr Atheroscler Rep. 2003;5(1):33–7.PubMedCrossRef
36.
go back to reference Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162(19):2197–202.PubMedCrossRef Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162(19):2197–202.PubMedCrossRef
38.
go back to reference Bayliss EA, Bronsert MR, Reifler LM, Ellis JL, Steiner JF, McQuillen DB, et al. Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med. 2013;16(4):412–8.PubMedCentralPubMedCrossRef Bayliss EA, Bronsert MR, Reifler LM, Ellis JL, Steiner JF, McQuillen DB, et al. Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med. 2013;16(4):412–8.PubMedCentralPubMedCrossRef
39.
go back to reference Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care. 2006;22(4):281–5.PubMed Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care. 2006;22(4):281–5.PubMed
40.
go back to reference Stavrou EP, Buckley N, Olivier J, Pearson SA. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open. 2012;2:e000880.PubMedCentralPubMedCrossRef Stavrou EP, Buckley N, Olivier J, Pearson SA. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open. 2012;2:e000880.PubMedCentralPubMedCrossRef
41.
go back to reference Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13:56.PubMedCentralPubMedCrossRef Schuling J, Gebben H, Veehof LJ, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13:56.PubMedCentralPubMedCrossRef
Metadata
Title
Inappropriate prescribing in patients accessing specialist palliative day care services
Authors
A. Todd
H. Nazar
S. Pearson
I. Andrew
L. Baker
A. Husband
Publication date
01-06-2014
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 3/2014
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-014-9932-y

Other articles of this Issue 3/2014

International Journal of Clinical Pharmacy 3/2014 Go to the issue